Dronabinol for PTSD Nightmares Is Promising, and the Dual Diagnosis Question Changes Everything
A Nature Medicine RCT shows dronabinol cuts PTSD nightmares. For the 46% of PTSD patients who also carry a...
dual diagnosis
GLP-1 Agonists Reduce AUD Hospitalizations — But Stopping Them Is a Clinical Decision We’re Not Ready For
Lancet Psychiatry data show GLP-1 agonists cut AUD hospitalizations, with protection lasting 182 days post-discontinuation. Here's what that means...
The Patients We’ve Been Afraid to Treat: PTSD, Psychosis, and What the STAR Trial Just Proved
The STAR trial enrolled 305 psychosis-PTSD patients clinicians long excluded from trauma therapy. The safety and efficacy data should...
The Patients We Told Ourselves Were Too Fragile
The STAR trial proves trauma-focused CBT is safe and effective in psychosis/PTSD patients—a dual-diagnosis population psychiatry has systematically excluded…
The Patient Tearing Up My Waiting Room Is Why Cebranopadol Matters
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
The Alzheimer’s Agitation Approval That Should Rewrite How We Think About Antipsychotics in Geriatric Psychiatry
Auvelity's FDA expansion into Alzheimer's agitation—peak sales now projected at $8B—exposes how long antipsychotics dominated a space where safer...